147ACTIVITIES
1ORGS REPRESENTED
50BILLS
Organizations represented
1Orgs whose LD-2 filings list Bailey as an active lobbyist, sorted by activity volume.
Bills they file on
50H.R. 126249 mentions
S. 93245 mentions
H.R. 167236 mentions
S. 86432 mentions
S. 52631 mentions
S. 52731 mentions
S. 109730 mentions
S. 109630 mentions
S. 109530 mentions
H.R. 616630 mentions
H.R. 642330 mentions
H.R. 326928 mentions
S. 227628 mentions
H.R. 648528 mentions
S. 4328 mentions
+ 35 more bills referenced in their activities
Topics in Filings
412Policy topics Bailey files on across all their LD-2 activities.
Medical Countermeasure Priority Review Voucher Reauthorization×146
CMMI: GLOBE and GUARD Models×112
National Coverage Determination×87
Antimicrobial Resistance×86
International Pricing Policies×84
R&D Funding for Medical Countermeasures×79
Lowering Drug Costs for American Families Act×77
Preserve Access to Affordable Generics and Biosimilars Act×73
Development and Procurement×72
Pharmacy Benefit Manager Transparency Act×72
CMMI Authority×72
Funding for Strategic National Stockpile×71
Show all 412 topics (+400 more) ▾
Most Favored Nation Drug Pricing Proposals×71
Prescription Pricing for the People Act×70
Pandemic Preparedness×70
Stop STALLING Act×68
FY 2026 Appropriations for Agencies×68
Biodefense/Biomedical/Emergency Preparedness Research×68
Centers for Disease Control and Prevention×67
Health Resources and Services Administration×67
FY 2026 Appropriations for Specific Issues×66
HHS Office of Infectious Disease and HIV/AIDS Policy×65
Pediatric Priority Review Voucher×57
Interagency Patent Coordination and Improvement Act×56
Administration for Strategic Preparedness and Response×56
Biomedical Advanced Research and Development Authority×56
340B Rebate Rule×56
Maintaining Investments and New Innovation×55
Development and Procurement Issues×54
Drug Supply Chain Management×52
Supply Chain Issues×52
Clinical Trial Data in China×51
Drug Pricing×50
Vaccines and Infectious Diseases×50
MCM PRV Reauthorization×43
Food & Drug Administration×42
Big Savings Act×42
FY 2025 Appropriations×41
Vaccine Injury Compensation Program×40
Risky Research Review Act×37
Quality & Distribution×36
Advanced Manufacturing×36
Drug Shortages×36
Supply Chain Integrity and Traceability×36
Patient Cost-Sharing and Implementation×36
Alternative Payment Arrangements for Gene Therapies×36
Drug Benefit Design×36
National Defense Authorization Act×36
Adult Immunization×36
Vaccine Safety net and Vaccine Infrastructure×36
Value of Vaccines and Vaccine Confidence×36
Pricing and Rebates×35
MCM Manufacturing & Capacity×35
Orphan Drug Tax Credit×35
Average Manufacturer Price Calculations×34
Support of Patient Premiums and Cost-Sharing Obligations×34
Let Injured Americans Be Legally Empowered×34
Vaccine Injury Compensation Modernization×34
Alternative Funding Programs×34
Biosimilar Red Tape Elimination Act×34
SAFE STEP Act×34
Vaccine Access Improvement Act×33
Funding for Women's Health Research×33
Medicare Drug Price Negotiation Act×33
Modernizing and Ensuring PBM Accountability×33
Value-based Contracting and Communications×32
Medicaid VBPs for Patients×32
FY 2026 Appropriations×31
Increasing Transparency in Generic Drug Application×31
Pandemic Preparedness -R&D Funding for Medical Countermeasures×30
Non-Opioid Analgesics Orphan Drug Issues×29
Biosecurity Modernization×29
Centers for Medicare and Medicaid×28
National Institutes of Health×28
Funding for Section 317×28
National Defense Authorization Act 2027×28
Biosimilars Competition×28
Data Privacy Working Group Draft×28
CMMI×28
Pediatric Priority Review Voucher Pandemic Preparedness×28
Restrictions on Intellectual Property Rights×26
Value-Based Purchasing×24
Executive Order on Access to Affordable Life-Saving Medications×22
Strengthening Innovation in Medicare and Medicaid Act×22
Biosimilar Copay×21
Interchangeability and Pharmacy Substitution×21
Promising Pathway Act×21
Medicare Part B Physician-Administered Products×21
Maternal Immunization×21
Program Implementation & Oversight×21
Mandating Exclusive Review of Individual Treatments×21
Advanced Research Projects Agency for Health×20
Bio COMPETES×20
CICP×20
PBM Reform×20
Coverage of Accelerated Approval Products×20
Patient Cost-Sharing and Smoothing×20
PROTECT 340B Act×20
Prescription Drug User Fee Act×20
China Biotechnology Regulations×19
Accelerated Approval Artificial Intelligence×19
COVID-19 Pricing Related Provisions×19
Countermeasures Injury Compensation Program×19
Vaccine Safety and Quality×19
VICP Loopholes×19
SUSTAIN 340B Act×19
Affordable Prescriptions for Patients Act×19
Access to Innovative Treatments Act×19
MCM PRV Program Reauthorization×18
WHO Pandemic Preparedness Accord Biosimilars×18
Reimbursement Cell & Gene Therapy×18
Encouraging Innovation Benefit Design to Lower Costs for Seniors Act×18
Vaccine and Antimicrobial Resistance Product Development and Incentives×18
Medicaid Drug Rebate Program×18
American Innovation and Jobs Act×18
Countermeasure Injury Compensation Fund Amendment Act×18
Pandemic Flu×18
One Big Beautiful Bill Act×18
TRIPS Waiver×17
State Strategic Stockpile Act×17
BIOSECURE Act×17
Expensing of R&D Expenditures×17
Biosimilars Red Tape Elimination Act×17
Vaccine Access & Compensation×17
Influenza Planning & Response×17
Project Bioshield×17
American Privacy Rights Act×17
FDA Hiring Flexibility×17
Medication Affordability and Patient Integrity Act×17
DRUG Act×17
FDA Modernization×17
Act 3.0 Medicaid×17
Innovation in Pediatric Drugs Act×17
Retaining Access and Restoring Exclusivity×17
Step Therapy×17
MCM R&D Incentives×17
Vaccine Quality Measure×17
Vaccine Safety×17
Foreign Drug Data Protection Laws×17
Diversity & Inclusion×16
Compounded Medicines×16
Helping Startups Continue to Grow Act×16
Equal Opportunity for All Investors Act×16
Decentralized Clinical Trials Drug Evaluation and Review×16
Precision Medicine Initiative Reimbursement and Coverage of Innovative Products×16
Disease X Act×16
Gain of function×16
SAFE Risky Research Act×16
Generic Drug Entry×16
Generic Drug Application Review Reforms×16
Incentives for Generic Entry Issues×16
Funding for Medical Countermeasures×16
Accelerated Approval Antimicrobial Resistance Artificial Intelligence×16
CFIUS and Foreign Investment Drug Pricing×16
Section 232×16
Climate Issues & impact on the agriculture and food sectors×15
House GOP RFI on Supply Chain×15
White House National Biodefense Strategy×15
ORPHAN Cures Act×15
Coverage and Reimbursement×15
Reference Pricing in Drug Reimbursement×15
World Intellectual Property Office×15
Genetic Resources, and Associated Traditional Knowledge×15
Section 317 Immunization Program×15
Vaccine Injury Compensation Program 340B Drug Discount Program×15
Compounding Pharmacies×15
Contract Manufacturing Ecosystem in the United States×15
Access to Innovative Treatments×15
PASTEUR ACT×15
WHO Pandemic Preparedness Accord Pandemic Preparedness×15
VICP/CICP Antimicrobial Resistance Biodefense Research×15
Vaccines and Infectious Diseases 340B Drug Discount Program×15
Most Favored Nation in Medicaid×15
NSCEB Recommendations Opioid Crisis×15
VICP/CICP Capital Formation Incentives×15
Cameron's Law Pandemic Preparedness Research & Development Tax Credit Reforms×15
CMMI Models: GLOBE and GUARD×14
Purple Book Draft×14
Consumer Data Privacy and Security Act×14
Diagnostics and Personalized Medicine Regulation and Oversight×14
PDUFA VII Implementation×14
PDUFA VIII Negotiations Drug Importation Drug Manufacturing×14
NSC/OSTP priorities×14
Nucleic acid synthesis security and biotechnology governance×14
Rare Disease Pilot Program Reimbursement and Coverage of Innovative Products×14
VICP/CICP Biodefense Research×14
CDC Reform×14
FDA Hiring Staffing Drug Importation Drug Manufacturing×14
Tariffs Foreign Drug Data Protection Laws Medicaid×14
Capital Formation Incentives×14
Accredited Investor Definition Review Act×14
Fair Investment Opportunities for Professional Experts Act×14
Capital Market Enhancements×14
Accredited Investor Definition×14
Public Float Threshold Update Small Business Innovation Research×14
INNOVATE Act×14
Small Business Innovation and Economic Security Act×14
Incentives for Domestics Manufacturing Orphan Drug Issues×14
R&D Payroll Credit Vaccines and Infectious Disease×14
Tariffs Foreign Agricultural Biotechnology Laws and Regulations×14
China Synthetic Biotech×14
Treaty on Intellectual Property×14
US-China IP Provisions United Nations World Trade Organization×14
Monoclonal Antibody Coverage and Utilization×13
Incentives for Sustainable Aviation Fuels×10
Biomass Crop Assistance, and Biorefineries×8
Rural Development×8
Food and Drug Administration, and Related Agencies Appropriations Act×8
Agricultural Biorefinery Innovation and Opportunity×8
SUPPORT Act×8
WHO Pandemic Preparedness Accord×8
Gene Editing×7
MCM PRV Program×7
FDA Approvals×6
Guidance, & Regulations×6
Sustainable Aviation Fuels Tax Credit×6
Tropical Disease Priority Review Voucher×6
Safe, and Secure American Bioeconomy×6
Give Kids a Chance Act×6
Pediatric Priority Review Voucher Program×6
Temporarily Refundable R&D Credit×6
HELP Copays Act×6
HHS Reorganization×6
Prescription Drug Price Relief Act×6
ASPR×6
Farm to Fly Act×5
Farm Bill Reauthorization×5
Genetically Engineered×5
Patent Thickets×5
Non-Opioid Analgesics×5
Administration Rebate Rule×5
Protected Classes×5
Most Favored Nation×5
National Institute of Health×5
BARDA×5
Farm Bill×4
Efficient Science-Based Review of Biotech Products×4
FY 2026 Appropriations Funding for Antimicrobial Resistance×4
Biofuels and SAF×4
IRA Tax Credits×4
Decentralized Clinical Trials×4
FDA Hiring Flexibility Drug Importation Drug Manufacturing×4
VICP×4
Lower Costs×4
Executive Order on Achieving Efficiency Through State and Local Preparedness×4
340B Accountability Act×4
American Innovation and R&D Competitiveness Act×4
Fair Prescription Drug Prices for Americans Act×4
Creating Hope Reauthorization×4
Emerging New Threats and×4
Orphan Drug Issues×4
Finding Orphan-Disease Remedies with Antifungal Research and Development×4
National Defense Authorization Act 2026×4
Food & Ag National Security×3
International Consistency of Regulations×3
EPA proposed revisions to regulations×3
USMCA Review×3
Pioneering Antimicrobial Subscriptions to End Upsurging Resistance×3
Reasonable Pricing Clauses in BARDA Contracts×3
Climate Change×3
House GOP RFI on Data Privacy×3
COVID-19 Lessons Learned×3
MCM PRV×3
Coverage and Reimbursement Orphan Drug Issues×3
Orphan Drug Tax Credit Pandemic Preparedness×3
Medical Countermeasures PRV Reauthorization×3
BSUFA Negotiations×3
Compounded Medicines Drug Patenting×3
Global Fairness in Drug Pricing Act×3
PPRV×3
Bill to address patent thickets×3
Medicare Negotiation and Competitive Licensing Act×3
ASPR FY 2026 Appropriations for Specific Issues×3
Office of Biopesticides and Pollution Prevention Division×2
Biotechnology and Agriculture Trade Program×2
Farm Bill Programs Energy Title IX×2
NextGen Aircraft Technology×2
Fuels & Metrics×2
Biomanufacturing and Jobs Act×2
Investment Tax Credit×2
Biomass Programs×2
340B Drug Discount Program×2
Biosecurity Infrastructure for Operational×2
NDAA×2
MINI Act×2
Medicaid Drug Rebate Program Rule×2
More Cures Act×2
Biodefense Research×2
Funding for Biodefense/Biomedical/Emergency Preparedness Research×2
American Innovation Act×2
Small Entity Update Act×2
Expanding Access to Capital Act×2
Cell & Gene Therapy×2
Most Favored Nation Foreign Drug Data Protection Laws×2
Project Bio Shield×2
AMMTO×2
BETA×2
Funding for Biofuels×2
Improving Data Accessibility Through Advancements×2
Drug Evaluation and Review×2
Drug Importation Drug Manufacturing×2
Stronger Patents Act×2
Protecting Patient Access to Cancer and Therapies×2
More Transparency Act×2
VICP CICP×2
Family Vaccine Protection Act×2
China Synthetic Biotech Tariffs Trade Relations×2
National Institutes of Health FY 2026 Appropriations for Specific Issues×2
Avian Flu×1
General Climate Change×1
Mexico Decree Banning Genetically Modified Corn Funding for the USDA×1
FY 2026 Appropriations Genetically Engineered×1
EPA Regulatory Approach to Gene Editing×1
FDA Proposed guidance on Gene Editing×1
USDA Regulatory Approach to Gene Editing Interagency Coordination×1
DOE and USDA Interagency Research Act×1
Regulatory Treatment of Gene Edited Products×1
Regulatory Treatment of Biostimulants United States-Mexico-Canada Agreement×1
Funding for Antimicrobial Resistance×1
FY 2026 Appropriations Pandemic Preparedness×1
Bioenergy Technology Office×1
Environmental Energy R&D×1
Funding for Renewable Materials/Bio-based Products×1
Fighting Climate Change through Biotechnology Innovation Funding for Biofuels×1
Mitigating Climate Change through Biotechnology Innovation Funding for Biofuels×1
Program & Oversight×1
American Pandemic Preparedness Plan×1
FY 2026 Appropriations Data Privacy×1
Clinical Trial Diversity Drug Evaluation and Review×1
CICP Funding for FDA×1
User Fees Funding for Health Resources and Services Administration×1
Funding for Womens Health Research International Reference Pricing Medicaid×1
Womens Health Research Pandemic Preparedness×1
General Cell & Gene Therapy×1
FY 2026 Appropriations Clinical Trial Data in China Data Privacy×1
General Diversity & Inclusion×1
Clinical Trial Diversity×1
General Drug Evaluation and Review×1
FY2025 Appropriations×1
PBN Reform×1
International Reference Pricing Foreign Drug Data Protection Laws×1
Regulatory Harmonization Funding for Antimicrobial Resistance×1
FY 2026 Appropriations International Reference Pricing Issues×1
Innovation and Pediatric Drugs Act×1
Infectious Disease Therapies Research and Innovation Act×1
Adjusting the well-known seasoned issues×1
Definition to allow for a larger financing round using×1
Net Operating Loss Advance Refunds×1
General Pandemic Preparedness Renewable Chemicals/Bio-based Products×1
Tax Relief for American Families and Workers Act×1
R&D Payroll Credit Vaccine Injury Compensation Program×1
Patent Thickets Drug Pricing×1
Regulatory Harmonization Medicaid×1
Dept of Interior×1
Dept of Energy×1
Dept of Transportation×1
USDA Avian Flu×1
USDA×1
APHIS×1
Foreign Animal Disease Efforts to expand the Bio Economy & Bio Manufacturing×1
Department of Energy×1
Department of Transportation×1
USDA FY 2026 Appropriations for Specific Issues×1
Environment and Energy R&D×1
Renewable Materials/BIO-based Products×1
Renewable Chemicals/Bio-based Products Renewable Chemicals/Bio-based Products×1
Efforts to expand the Bio Economy & Bio Manufacturing×1
BARDA FY 2026 Appropriations for Specific Issues×1
Section 317 Immunization Program 340B Drug Discount Program×1
Accelerated Approval Access to non-human Primates×1
Climate Change Data Privacy×1
PDUFA×1
FDA Reform×1
Compounding & Counterfeit Medicines Drug Patenting×1
Rare Disease Pilot Program Pandemic Preparedness×1
End Price Gauging for Medications Act×1
SMART Prices Act×1
HHS Reorganization Pandemic Preparedness×1
VICP Biofuels and SAF×1
Carbo Capture Utilization Parity Capital Formation Incentives×1
R&D Payroll Credit×1
Net Operating Loss×1
Vaccines and Infectious Disease×1
National Institute of Health FY 2026 Appropriations for Specific Issues×1
Reimbursement Cell & Gene Therapy Data Privacy×1
Clinical Trial Modernization×1
Drug Rebate Program Rule×1
HHS Reorganization CDC Reform×1
Prescription Drug Pricing for the People Act×1
Most Favored Nation Foreign Agricultural Biotechnology Laws and Regulations×1
Protecting Americans Data from Foreign Adversaries Act×1
B5 Coalition on Supply Chain Resiliency×1
340B ACCESS Act×1
Synthetic Nucleic Acid Synthesis Screening×1
PDUFA VIII Negotiations×1
Drug Manufacturing×1
Biologics Competition Act×1
Enhanced Access to Affordable Medicines Act×1
Most Favored Nation Pricing Opioid Crisis×1
Reimbursement and Coverage of Innovative Products×1
Administrative Rebate Rule×1
MCM PRV Program CDC Reform×1
340B Rebate Pilot Program×1
FDA Hiring Flexibility Drug Manufacturing×1
Most Favored Nation Pricing×1
Vaccine Access×1
Vaccines for Children Program×1
CMMI Models×1
Intellectual Property International Enforcement×1
Bilateral Trade Negotiations×1
US-China IP Provisions×1
Word Health Organization×1
Issue mix
LDA general-issue codes weighted by activity count.
Budget/Appropriations18
Health Issues18
Homeland Security18
Medical/Disease Research/Clinical Labs18
Medicare/Medicaid18
Taxation/Internal Revenue Code17
Trade (domestic/foreign)16
Small Business14
Agriculture2
Chemicals/Chemical Industry2